Vocal.

Pharma is in such a data mood today…

A few observations on our industry's appetite for data from a recent conversation between colleagues in Europe.

Prescription Drug Pricing: “The Times They Are A Changin”

The drug pricing debate in DC has intensified, and the pharmaceutical industry has become the prime target of bipartisan outrage.

'ICER' strikes again - Scandal time?

The drug-price watchdog ICER just issued a "Report on Unsupported Price Increases". The 'study' made the headlines, but it is problematic.

Real World Evidence: From Market Access to Drug Approval

This analysis outlines recent developments in the use of real-world evidence (RWE) and the sizeable impact it stands to make the industry.

PharmaVoice 'Year in Preview'- Interview

Thanks to the team at PharmaVoice for the interview for the "Year in Preview" issue. My two cents on multi-stakeholder commercial models.

The Shifting Landscape for Outcomes-Based Contracting – A US Market Assessment

Neumann, U. (2018). The Shifting Landscape for Outcomes-Based Contracting – A US Market Assessment (Whitepaper). Analytica Laser.

Blockchain in Pharma... Blockchain for Market Access? - 5 Thoughts

5 observations as to where we are today, and what might lie ahead for Blockchain in Pharmaceutical Market Access.

Class Cmm Drugs in Italy: Purchase and Prescription Behaviour in Hospitals

Value in Health, Vol. 21, Suppl. 3 S. 165, October, 2018 · Jan 1, 2018

Jack Whelan beat cancer.

Like anyone who knew him in our field, I am tragically saddened by the passing of Jack Whelan last Thursday. The fact that this day would ev

Payer-Pharma Perspectives on Outcomes-based Contracting. Stakeholder Insights.

Neumann, U. (2017). Payer-Pharma Perspectives on Outcomes-based Contracting. Stakeholder Insights. (Whitepaper). Analytica Laser.

Help Ukraine